-
Patent Agency Ranking
公开(公告)号：US20240383967A1
公开(公告)日：2024-11-21
申请号：US18666067
申请日：2024-05-16
Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
Inventor： Yong ZHANG
Abstract: Embodiments of the invention include a fusion protein and/or cathepsin S inhibitors that comprise an antibody scaffold protein comprising a full-length antibody or a Fab fragment, and a propeptide of procathepsin S, such that the propeptide of procathepsin S is grafted into one or more complementarity determining regions (CDR) of the full-length antibody, or the propeptide of procathepsin S is grafted onto an N-terminus or C-terminus of a light chain and/or a heavy chain of the Fab fragment.
-
公开(公告)号：US20250092143A1
公开(公告)日：2025-03-20
申请号：US18580889
申请日：2022-07-22
Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
Inventor： Yong ZHANG , Qinqin CHENG
Abstract: The disclosure provides for an engineered extracelluar vesicle and methods of using the same where the engineered extracellular vesicle comprises a first fusion protein having the formula A-B-C, wherein A is a first antibody moiety, B is a second antibody moiety, and C is a first exosomal protein transmembrane domain; and a second fusion protein comprising the formula D-E-F, wherein D is a first protein binding moiety, E is a second exosomal membrane protein transmembrane domain, and F is a second protein binding moiety; wherein both the first fusion protein and the second fusion protein are displayed on a surface of the engineered extracellular vesicle, and the first antibody moiety and the second antibody moiety separately bind to a an immune cell marker protein and a cancer cell surface-marker protein, and the first binding protein moiety and the second protein binding moiety separately bind to a second immune cell marker protein and a second cancer cell surface-marker protein.
-
公开(公告)号：US20240148878A1
公开(公告)日：2024-05-09
申请号：US18493223
申请日：2023-10-24
Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
Inventor： Yong ZHANG
CPC classification number: A61K47/549 , A61K47/60 , A61K47/64
Abstract: A poly ADP-ribose polymerase (PARP)-effector molecule conjugate comprising an automodified PARP having a plurality of poly ADP-ribose (ADPr) polymers on a surface of the automodified PARP, wherein the poly ADPr polymers comprise two or more 3′-azido NAD+ moieties, and the effector molecule is conjugated to at least one of the 3′-azido NAD+ moieties of the poly ADPr polymers while at least one of the 3′-azido NAD+ moieties remain unconjugated.
-
公开(公告)号：US20240277862A1
公开(公告)日：2024-08-22
申请号：US18439252
申请日：2024-02-12
Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
Inventor： Yong ZHANG
CPC classification number: A61K47/6815 , A61K38/45 , A61K47/6849 , A61K47/6889 , A61P35/00 , C07K16/2809 , C07K16/32 , C12Y204/02039
Abstract: A poly ADP-ribose polymerase (PARP)-antibody conjugate including an automodified PARP having a plurality of poly ADP-ribose (ADPr) polymers, wherein the poly ADPr polymers comprise a plurality of 3′-azido ADP-ribose moieties; and one or more antibody molecules conjugated to one or more of the plurality of 3′-azido ADP-ribose moieties, wherein the one or more antibody molecules specifically bind to both a cancer cell surface marker protein and an immune cell surface marker protein, and wherein at least one of the plurality of 3′-azido ADP-ribose moieties is not conjugated to the antibody molecules.
-
公开(公告)号：US20230128344A1
公开(公告)日：2023-04-27
申请号：US17996313
申请日：2021-05-10
Applicant: University of Southern California
Inventor： Yong ZHANG , Zhefu DAI , Xiao-Nan ZHANG
Abstract: Antibody-drug conjugates, compositions thereof, and methods use. The antibody-drug conjugates include a fusion protein comprising an antibody covalently linked to an ADP-ribosyl cyclase protein via a peptide linker moiety at one or more of a C-terminus or N-terminus of a heavy or light chain of the antibody, a NAD or NMN analogue, and a payload such that the NAD or NMN analogue is conjugated to both the payload and the ADP-ribosyl cyclase protein.
-
-
-
-
Search Results
5
records
(took 0.015 seconds)
